Technology
Health
Biotechnology

Dicerna Pharmaceuticals

$13.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.38 (2.86%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell DRNA and other stocks, options, ETFs, and crypto commission-free!

About

Dicerna Pharmaceuticals, Inc. Common Stock, also called Dicerna Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. Read More The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.

Employees
78
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
906.52M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
596.90K
High Today
$13.69
Low Today
$13.21
Open Price
$13.39
Volume
124.89K
52 Week High
$17.98
52 Week Low
$8.71

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2014 IPO
US
North America

News

Simply Wall StMar 20

Will Dicerna Pharmaceuticals, Inc.’s (NASDAQ:DRNA) Earnings Grow In The Years Ahead?

The latest earnings update Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released in December 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Below, I’ve presented key growth figures on how market analysts perceive Dicerna Pharmaceuticals’s earnings growth outlook over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding...

64
MarketWatchMar 13

Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -26.09% and -81.60%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

90
Seeking AlphaMar 12

Dicerna Pharmaceuticals (DRNA) Presents At Cowen And Company 39th Annual Health Care Conference - Slideshow

The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this event. 1 22 Click to enlarge Notes:...

5

Earnings

-$0.92
-$0.69
-$0.45
-$0.22
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.